Stock ONCY ONCOLYTICS BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Oncolytics Biotech Inc. Nasdaq

Equities

ONCY

CA6823108759

Market Closed - Nasdaq
Other stock markets
 21:00:00 25/06/2024 BST 		5-day change 1st Jan Change
1.01 USD 0.00% Intraday chart for Oncolytics Biotech Inc. -0.98% -25.19%
06-24 Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence MT
06-24 Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Oncolytics Biotech CEO Matt Coffey to Take Medical Leave of Absence
MT
Oncolytics Biotech President and CEO Coffey to Take Medical Leave of Absence
MT
Oncolytics Biotech Brief: Announcing President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
MT
Oncolytics Biotech Doses First Patient in Pelareorep Study Involving Modified FOLFIRINOX
MT
Oncolytics Biotech Brief: Says Dosed First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
MT
Oncolytics Biotech® Doses First Patient in Study of Pelareorep/FOLFIRINOX Combination Therapy in Pancreatic Cancer
PR
Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting
CI
Oncolytics Biotech Says ASCO Abstracts Highlight Pelareorep's Treatment Potential in Pancreatic Cancer
MT
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and Immunotherapeutic Mechanism of Action
AQ
Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders
PR
Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Pancreatic Cancer Trial
MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
CI
Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
MT
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
PR
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
CI
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA
MT
Oncolytics Biotech Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer
AQ
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million
MT
Transcript : Oncolytics Biotech Inc., Q1 2024 Earnings Call, May 09, 2024
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONC Stock
  4. ONCY Stock
  5. News Oncolytics Biotech Inc.